Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias

By sjmartinez • May 7, 2025

Zhang W, Li L, Muftuoglu M, Basyal M, Togashi N, Iwanaga K, Tanzawa F, Numata M, Bixby DL, Erba HP, Podoltsev N, Schiller GJ, Kumar P, Lesegretain A, Isoyama T, Seki T, Daver N, Andreeff M. Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias. Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-2764. Epub ahead of print. PMID: 40327322.

Tags: Hematology/Oncology, Publications

Related Posts

p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer

Muss HB, Sun C, Ding YC, Ji J, White TA, Nyrop K, LeBrasseur NK, Neuhausen SL, Mitin N, Sedrak MS. p16INK4a and DNA methylation clocks in[...]

Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization

Levi A, Nasr A, Cui Y, Abbas AA, Arouchian TT, Coveler AL, Pierce TL, Anderson BT, Collisson E, Davelaar J, Lo SK, Gaddam S, Gong[...]

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Bragagnoli AC,[...]